FUS and acute myeloid leukemia: Overall, these findings suggest that targeting GSPT1 could be a promising therapeutic strategy for certain pediatric AML subtypes and point to a possible role in the regulation of the stability and translation of critical fusion proteins such as RUNX1::RUNX1T1 or FUS::ERG.